CHCWM – Cancer & Hematology Centers of West Michigan

D361BC00001 (CAPITELLO-281)

A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency

CC-94676-  (Celgene)

CC-94676-  (Celgene) Description:  A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of CC-94676 In Subjects With Metastatic Castration-Resistant Prostate Cancer Mechanism of Action:  Oral Androgen Receptor Degrader Target Patient Population:  Prostate Cancer Study Design:  Drug is given orally daily.

C4391001 ( Pfizer)

Description:  A Phase 1/1B Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PF-07220060 as a Single Agent and As Part of Combination Therapy In Participants With Advanced Solid Tumors. Mechanism of Action:  CDK4 inhibitor Target Patient Population:   Metastatic Breast Cancer, NSCLC (adeno), Prostate cancer, Colorectal cancer, Liposarcoma and tumor types with CDK4

ST-101 (Sapience)

Description:  A Phase 1-2 Dose-Escalation and Expansion Study of ST101 in Patients with Advanced Unresectable and Metastatic Solid Tumors Mechanism of action:  Targets CEBP-beta, which is a transcription factor controlling multiple cellular processes (differentiation, cell survival and metabolism) Target Patient Population:  Breast (HR+), cutaneous melanoma, glioblastoma, prostate cancer Study Design:  Drug is administered IV every